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Background: Patients with end-stage renal disease (ESRD) due to lupus nephritis (LN-ESRD) may be followed by
multiple providers (nephrologists and rheumatologists) and have greater opportunities to receive recommended
ESRD-related care. We aimed to examine whether LN-ESRD patients have better quality of ESRD care compared to
other ESRD patients.
Methods: Among incident patients (7/05–9/11) with ESRD due to LN (n = 6,594) vs. other causes (n = 617,758),
identified using a national surveillance cohort (United States Renal Data System), we determined the association
between attributed cause of ESRD and quality-of-care measures (pre-ESRD nephrology care, placement on the
deceased donor kidney transplant waitlist, and placement of permanent vascular access). Multivariable logistic
and Cox proportional hazards models were used to estimate adjusted odds ratios (ORs) and hazard ratios (HRs).
Results: LN-ESRD patients were more likely than other ESRD patients to receive pre-ESRD care (71% vs. 66%; OR = 1.68,
95% CI 1.57-1.78) and be placed on the transplant waitlist in the first year (206 vs. 86 per 1000 patient-years; HR = 1.42,
95% CI 1.34–1.52). However, only 24% had a permanent vascular access (fistula or graft) in place at dialysis start
(vs. 36%; OR = 0.63, 95% CI 0.59–0.67).
Conclusions: LN-ESRD patients are more likely to receive pre-ESRD care and have better access to transplant, but are
less likely to have a permanent vascular access for dialysis, than other ESRD patients. Further studies are warranted to
examine barriers to permanent vascular access placement, as well as morbidity and mortality associated with temporary
access, in patients with LN-ESRD.Background
Among end-stage renal disease (ESRD) patients, receipt
of pre-ESRD care [1-9], access to kidney transplantation
[10-15], and permanent vascular accesses for dialysis,
which include arteriovenous fistulae (AVFs) and grafts
[16-23], are all associated with better patient outcomes
and lower healthcare costs. Benchmarks for ESRD
healthcare quality are provided in Healthy People 2020
(www.healthypeople.gov) [24]. Further, Centers for
Medicare & Medicaid Services (CMS) is incentivized to
promote quality of care due to universal coverage of
ESRD care for all eligible U.S. patients. Accordingly,* Correspondence: laura.plantinga@emory.edu
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unless otherwise stated.CMS mandates ESRD pay-for-performance [25] and
quality improvement projects addressing quality of ESRD
care that are regionally implemented through its 18 ESRD
Networks. Since 2005, CMS has also collected information
on quality-of-ESRD-care measures on all incident ESRD
patients via the CMS Medical Evidence Report (CMS
Form 2728), which is completed for all patients at the start
of ESRD treatment.
Recently, we reported on the sociodemographic and
geographic predictors of quality of ESRD care in the
population with ESRD attributed to lupus nephritis
(LN-ESRD) [26], and others have reported on placement
on the deceased donor kidney transplant waitlist among
these patients [27,28]. However, the translation of these
measures among LN-ESRD patients has not been com-
pared to that among other ESRD patients. Translational. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ter, in patient populations treated by multiple specialty
providers, such as those with LN-ESRD, relative to the
overall population. However, a similar U.S. population
of ESRD patients in terms of age and race as well as re-
ceipt of multi-provider treatment—those with ESRD
secondary to sickle cell disease—was shown to have
poorer quality of care than patients with ESRD due to
other causes [29]. A comparison among patients with
ESRD due to LN vs. other causes is important because
nephrologists could partner with rheumatologists, who
currently have few guidelines to address the preparation
for ESRD among their systemic lupus erythematosus
(SLE) patients [30], and other providers to address iden-
tified gaps in the quality of ESRD care among these pa-
tients. Thus, we sought to compare the translation of
ESRD quality-of-care measures among U.S. patients
with LN-ESRD vs. ESRD due to other causes.
Methods
Study population and data sources
Data from the most recent (2005) version of the CMS-
2728, completed on all treated U.S. incident ESRD pa-
tients, were obtained from the United States Renal Data
System (USRDS) [15]. Patient consent was not re-
quired or possible in this secondary analysis of de-
identified data, and the Emory Institutional Review
Board approved the study protocol (IRB00063645). A
total of 675,889 incident ESRD patients initiated treat-
ment from 7/1/05 to 9/30/11 with available data on
primary attributed cause of ESRD. Of these, 81,333
(12.0%) had unknown pre-ESRD nephrology care sta-
tus and were excluded from these analyses (Figure 1).
For analyses of measures of access to kidney transplant-
ation (informed of transplant options and placement on
the deceased donor kidney waitlist), those who received
transplants without prior dialysis (n = 17,504), were placed
on the waitlist prior to starting dialysis (n = 19,431), or
were aged ≥70 years (n = 246,891) were excluded from
the 675,889 ESRD patients, leaving 392,513 for ana-
lyses (Figure 1). For analyses of permanent vascular ac-
cess, those who received transplants without prior
dialysis (n = 17,504) or treated with peritoneal dialysis
instead of hemodialysis (n = 42,360) were excluded,
leaving 616,025 for analysis (Figure 1).
Primary attributed cause of ESRD, quality-of-care
measures (nephrology care prior to ESRD, being in-
formed of transplant options, and vascular access at
first dialysis), race/ethnicity, insurance, and clinical
factors were all obtained from the CMS-2728 through
the USRDS. Information on placement on the de-
ceased donor kidney transplant waitlist was obtained
from United Network for Organ Sharing (UNOS)
data through the USRDS.Study variables
Attributed cause of ESRD
The exposure of interest was the primary attributed
cause of ESRD, which was defined by International
Classification of Diseases (ICD)-9 codes listed on the
CMS-2728. LN-ESRD was defined as ESRD attributed
to secondary glomerulonephritis due to SLE (CMS-2728
ICD-9 code = 710.0). ESRD due to other GN was
included as a separate category for comparison with
LN-ESRD due to potential similarities in patient popula-
tion, disease course, and treatment. GN-ESRD was de-
fined by CMS-2728 ICD-9 codes for glomerulonephritis
(582.9, 582.1, 583.1, 583.21, 583.22, 583.81, 583.82,
583.4, 580.0, and 582.0) or secondary glomerulonephritis/
vasculitis (excluding LN-ESRD; 287.0, 710.1, 283.11,
446.0, 446.4, 583.92, 446.20, 446.21, and 583.91). All other
causes of ESRD, which served as the referent group in
main analyses, included all other ICD-9 codes as listed on
the CMS-2728. Since the majority of incident ESRD in the
United States is attributed to diabetes or hypertension
(72%) or GN (6%) [15] and the remaining attributed
causes represent a fairly diverse group of ESRD etiologies
such as cystic kidney disease, we conducted sensitivity
analyses including only patients with ESRD attributed to
diabetes (250.4x) or hypertension or large vessel disease
(CMS-2728 ICD-9 code = 403.91, 440.1, 583.81, 593.83)—
representing typical U.S. ESRD patients—in the referent
group.
Quality-of-care measures
The outcomes of interest were quality-of-care measures
related to pre-ESRD care, access to transplant, and per-
manent vascular access placement. Pre-ESRD nephrol-
ogy care was defined by an answer of “Yes” to item 18b
on the CMS-2728: “Prior to ESRD therapy: was the
patient under the care of a nephrologist?” Duration of
pre-ESRD care (>12 months, 6–12 months, <6 months,
or none) was also recorded. Whether patients were in-
formed of transplant option was defined by CMS-2728
item 26: “Has patient been informed of kidney transplant
options?” with possible responses of “Yes” and “No.”
Date of placement on the deceased donor transplant
waitlist was determined from UNOS data and used to
calculate time to placement on the transplant waitlist
(date of placement – first ESRD service date). Censoring
occurred at death or at the end of follow-up (9/30/11;
median follow-up, 1.9 years). Finally, vascular access was
determined from CMS-2728 item 18d: “What access was
used on first outpatient dialysis?” with possible responses
of “AVF,” “Graft,” “Catheter,” and “Other” and two
additional prompts for maturing permanent accesses in
place (“Is maturing AVF present?” and “Is maturing graft
present?”). Permanent vascular access was defined as
AVF or graft used or in place on first dialysis.
Figure 1 Selection of analytic populations for examination of the association of attributed cause of ESRD with pre-ESRD nephrology
care, access to transplant, and vascular access, among U.S. ESRD patients initiating treatment 7/05–9/11. Numbers by arrows represent
the numbers of patients excluded by indicated criteria; numbers in boxes represent those remaining after prior exclusions.
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Incident age and sex were obtained from the USRDS
patient demographics file. Race/ethnicity (defined as
white, black, Hispanic, and other), insurance prior to
ESRD (defined as private, Medicaid, none, or other),
smoking status, BMI, presence of comorbid conditions,
and serum albumin and hemoglobin at the start of ESRD
were obtained from the CMS-2728. Recovery of renal
function, from the patient history file, was defined as
any discontinuation of renal replacement therapy over
the course of ESRD, regardless of whether treatment was
later continued.
Statistical analysis
Patient characteristics including sociodemographics and
clinical factors were summarized overall and by attrib-
uted cause (LN-ESRD, GN-ESRD, and other ESRD).
Quality-of-care measures were summarized overall and
by incident year, with tests for trend. Odds ratios (ORs)
and confidence intervals (CIs) for the associations be-
tween dichotomous outcomes (pre-ESRD nephrology
care, informed of transplant options, and permanent
vascular access placement) were estimated with multi-
variable logistic regression models. For placement on
the transplant waitlist, time-to-event analyses were
used. To address potential non-proportionality [by tests
of Schoenfeld residuals (P < 0.001) and examination of
log-log curves], hazard ratios (HRs) and CIs were obtained
from multivariable Cox proportional hazards modelsbefore and after 1 year of ESRD treatment. Factors that
were associated with both attributed cause and quality-
of-care measures and were not thought a priori to be
mediators of the association were considered potential
confounders. Sensitivity analyses (i) with diabetes and
hypertension as the referent group (see above); (ii) re-
moving those who recovered renal function [31]; (iii)
with further adjustment for albumin (missing on 23%
of patients); and (iv) with allowances for non-linear as-
sociations with age and interactions between age and
sex; as well as measure-specific sensitivity analyses,
were also conducted. Stata v. 13 (StataCorp, College
Station, TX) was used for all analyses.
Results
Characteristics of the study population by attributed
ESRD cause
Patients with ESRD due to LN had a mean age of
40 years and were, on average, 14 and 24 years younger
than patients with ESRD due to other glomeruloneph-
ritis (GN) and patients with ESRD due to other causes,
respectively (Table 1). The majority of LN-ESRD patients
were female, compared to fewer than half of GN-ESRD
and other ESRD patients (Table 1). Similarly, half of LN-
ESRD patients were black, compared to approximately
one-quarter of GN-ESRD and other ESRD patients
(Table 1). Cardiovascular disease was far more common
in other ESRD patients than among LN- or GN-ESRD
patients, and those with LN-ESRD were less likely to
Table 1 Characteristics of U.S. ESRD patients with attributed causes of lupus nephritis, other types of
glomerulonephritis, and all other causes, 7/05–9/11
Characteristic Overall Attributed cause of ESRD*
LN Other GN All other
N 675,889 6,594 51,537 617,758
Sociodemographic
Age, years, mean (SD) 62.5 (16.0) 39.6 (15.4) 53.9 (18.9) 63.4 (15.3)
Sex, %
Female 43.7% 81.1% 40.7% 43.5%
Male 56.3% 18.9% 59.3% 56.5%
Race/ethnicity, %
White 52.9% 24.7% 57.8% 52.7%
Black 28.1% 49.7% 22.5% 28.3%
Hispanic 13.4% 17.7% 12.3% 13.4%
Other 5.7% 7.9% 7.4% 5.6%
Insurance at ESRD start, %
Private 31.3% 37.4% 41.8% 30.3%
Medicaid 24.5% 32.8% 18.6% 24.9%
Medicare/other 36.8% 18.4% 30.0% 37.5%
None 7.5% 11.5% 9.6% 7.3%
Clinical
Smoking, %
No 93.8% 95.7% 92.7% 93.9%
Yes 6.2% 4.3% 7.3% 6.1%
BMI, kg/m2, mean (SD) 28.9 (7.8) 26.9 (7.4) 28.1 (7.5) 29.0 (7.8)
Hypertension, %
No 15.4% 16.4% 17.0% 15.3%
Yes 84.6% 83.6% 83.0% 84.7%
CVD, %
No 57.8% 81.4% 75.8% 56.0%
Yes 42.2% 18.6% 24.2% 44.0%
Albumin, g/dl, mean (SD) 3.1 (0.7) 2.9 (0.8) 3.2 (0.8) 3.1 (0.7)
Hemoglobin, g/dl, mean (SD) 10.0 (1.7) 9.5 (1.7) 10.0 (1.8) 10.0 (1.6)
Recovery of renal function, %
No 95.5% 93.1% 95.9% 95.5%
Yes 4.5% 6.9% 4.1% 4.5%
LN, lupus nephritis; GN, glomerulonephritis; BMI, body mass index; CVD, cardiovascular disease, including pericarditis; p-y, person-years.
*P < 0.001 for all comparisons across attributed cause, by ANOVA, chi-square, or log-rank test.
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(BMI) and lower levels of albumin and hemoglobin than
those with GN-ESRD or other ESRD (Table 1).
Association of attributed cause of ESRD with quality-of-care
measures
Pre-ESRD care
Overall, about two-thirds of U.S. ESRD patients received
pre-ESRD nephrology care, with LN-ESRD (71%) andGN-ESRD (69%) patients more likely to receive pre-
ESRD care than other ESRD (65%) patients (Table 2).
LN- and GN-ESRD patients were also more likely to
receive greater duration of pre-ESRD care than
other ESRD patients (>12 months, 36% and 35% vs.
27%; >6 months, 57% and 56% vs. 51%; P < 0.001
for both; not shown in table). Receipt of pre-ESRD
care among incident patients increased slightly from 2005
to 2011 for each attributed cause, although the trend was
Table 2 Attainment of quality-of-care measures by cause of ESRD (lupus nephritis, other glomerulonephritis, and all
other causes) and by incident year, among U.S. ESRD patients initiating treatment 7/05–9/11
Quality-of-care measure* Entire follow-up
(7/05–9/11)
Incident year Ptrend
2005 2006 2007 2008 2009 2010 2011
Pre-ESRD nephrology care, %
All ESRD (n = 594,556) 65.7% 65.9% 65.6% 65.0% 65.0% 65.5% 65.9% 67.7% <0.001
ESRD attributed to:
Lupus nephritis (n = 5,939) 71.1% 72.2% 70.2% 71.7% 70.3% 73.1% 68.9% 72.3% 0.96
Other glomerulonephritis (n = 48,031) 69.3% 69.3% 69.1% 67.7% 69.2% 69.0% 70.4% 71.2% 0.002
All other causes (n = 540,586) 65.3% 65.5% 65.2% 64.6% 64.6% 65.1% 65.5% 67.4% <0.001
Informed of transplant options, %
All ESRD (n = 392,513) 78.9% 76.9% 76.2% 76.6% 78.0% 80.5% 81.4% 82.4% <0.001
ESRD attributed to:
Lupus nephritis (n = 5,619) 84.8% 87.0% 82.6% 82.6% 84.8% 85.9% 86.5% 85.8% 0.07
Other glomerulonephritis (n = 32,325) 83.6% 82.3% 82.1% 81.6% 83.6% 84.5% 85.1% 87.0% <0.001
All other causes (n = 354,569) 78.3% 76.1% 75.5% 76.0% 77.4% 80.1% 81.1% 82.0% <0.001
Placement on the kidney transplant waitlist, events/1000 p-y
All ESRD (n = 392,513) 97 83 88 91 99 114 122 95 <0.001
ESRD attributed to:
Lupus nephritis (n = 5,619) 206 194 177 208 210 230 263 180 0.07
Other glomerulonephritis (n = 32,325) 203 162 181 190 211 240 277 232 <0.001
All other causes (n = 354,569) 86 74 78 80 88 102 108 82 <0.001
Permanent vascular access used or in place at ESRD start, %
All ESRD (n = 616,025) 35.9% 37.4% 36.7% 35.4% 34.3% 35.1% 36.4% 37.4% 0.89
ESRD attributed to:
Lupus nephritis (n = 5,624) 24.4% 22.3% 25.7% 23.9% 23.5% 24.3% 25.5% 25.3% 0.45
Other glomerulonephritis (n = 41,824) 37.7% 40.3% 38.6% 37.4% 36.1% 36.7% 37.1% 39.6% 0.83
All other causes (n = 568,577) 35.9% 37.3% 36.7% 35.4% 34.2% 35.0% 36.5% 37.4% 0.11
ESRD, end-stage renal disease; p-y, patient year. *P < 0.001 for all overall and within-year comparisons of measures across attributed cause of ESRD.
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adjustment for potential sociodemographic and clinical
confounders, those with LN-ESRD were nearly 70% more
likely than other ESRD patients to receive pre-ESRD care,
whereas GN-ESRD patients were only about 20% more
likely to receive this care (Table 3). The associations were
slightly stronger for longer duration [pre-ESRD care ≥12
vs. <12 months: LN-ESRD, OR = 1.82, (95% CI, 1.70–
1.92); GN-ESRD, OR = 1.42 (95% CI, 1.39–1.45)] and
weaker for shorter duration [pre-ESRD care ≥6 vs.
<6 months: LN-ESRD, OR = 1.50 (95% CI, 1.42–1.59);
GN-ESRD, OR = 1.21 (95% CI, 1.18–1.23)]. Results from
other sensitivity analyses were similar to the primary ana-
lyses (Table 4).
Access to transplant
Overall, 79% of U.S. ESRD patients were informed of
transplant options at the start of ESRD, with 85%, 84%,
and 78% of patients with ESRD due to LN, GN, and
other causes being informed. Absolute increases of about5% in being informed of transplant options were seen
over study follow-up for all incident ESRD patients, al-
though the trend was marginally statistically significant
for LN-ESRD patients (P = 0.07; Table 2). With adjust-
ment, ESRD patients with LN and GN were 10% and
19% more likely than those with other causes to be in-
formed of the transplant options (Table 3). Estimates
were nearly identical when patients aged ≥70 years were
included, to account for increasing transplantation in
older adults [32] [LN-ESRD, OR = 1.10 (95% CI, 1.02–
1.19); GN-ESRD, OR = 1.19 (95% CI, 1.15–1.23)], and re-
sults were similar in other sensitivity analyses as well
(Table 4).
Incidence of placement on the kidney transplant wait-
list was 97 per 1000 patient-years overall but was more
than twice as high among LN-ESRD and GN-ESRD pa-
tients as compared to other ESRD patients (Table 2).
Placement on the waitlist increased over time among pa-
tients with all causes of ESRD, although the trend was
marginally statistically significant for LN-ESRD patients
Table 3 Risk ratios for attributed causes of lupus nephritis and other glomerulonephritis vs. other causes of ESRD,
among U.S. ESRD patients initiating treatment 7/05–9/11
Quality of care measure Risk ratio for attributed cause of ESRD (95% CI)
Unadjusted Adjusted*
Sociodemographic Sociodemographic and clinical
Pre-ESRD care, yes vs. no (odds ratio)
All other causes 1.00 (ref) 1.00 (ref) 1.00 (ref)
Lupus nephritis 1.64 (1.54–1.74) 1.51 (1.42–1.61) 1.68 (1.57–1.78)
Other glomerulonephritis 1.26 (1.23–1.28) 1.19 (1.17–1.22) 1.22 (1.19–1.24)
Informed of transplant options, yes vs. no (odds ratio)
All other causes 1.00 (ref) 1.00 (ref) 1.00 (ref)
Lupus nephritis 1.10 (1.02–1.19) 1.09 (1.01–1.18) 1.10 (1.02–1.19)
Other glomerulonephritis 1.19 (1.15–1.23) 1.21 (1.17–1.25) 1.19 (1.15–1.23)
Time to placement on the kidney transplant waitlist (hazard ratio)
In 1st year of ESRD
All other causes 1.00 (ref) 1.00 (ref) 1.00 (ref)
Lupus nephritis 2.29 (2.15–2.43) 1.47 (1.39–1.57) 1.42 (1.34–1.52)
Other glomerulonephritis 2.73 (2.66–2.80) 2.00 (1.95–2.05) 1.91 (1.86–1.96)
After 1st year of ESRD
All other causes 1.00 (ref) 1.00 (ref) 1.00 (ref)
Lupus nephritis 2.45 (2.29–2.63) 1.60 (1.49–1.72) 1.56 (1.45–1.67)
Other glomerulonephritis 1.90 (1.84–1.97) 1.45 (1.40–1.50) 1.39 (1.35–1.44)
Permanent vascular access used/in place, yes vs. no (odds ratio)
All other causes 1.00 (ref) 1.00 (ref) 1.00 (ref)
Lupus nephritis 0.57 (0.53–0.61) 0.58 (0.55–0.62) 0.63 (0.59–0.67)
Other glomerulonephritis 1.07 (1.05–1.10) 1.07 (1.05–1.10) 1.10 (1.07–1.12)
*Sociodemographic: age, race, sex, and insurance; clinical: body mass index, cardiovascular disease (including pericarditis), and hemoglobin.
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patients with LN and GN but was much shorter among
both groups of patients compared to other ESRD pa-
tients (Figure 2). Adjusted analyses showed that the rate
of placement on the waitlist among LN-ESRD patients
was 42% higher than that among other ESRD patients in
the first year of ESRD; this relatively increased rate
was even higher (56%) after the first year (Table 3). In
comparison, GN-ESRD patients had nearly twice the
rate of placement on the kidney transplant waitlist as
other ESRD patients in the first year but only a ~40%
higher rate after the first year (Table 3). When those
aged ≥70 years were included, results were nearly
identical [within first year: LN-ESRD, OR = 1.42 (95%
CI, 1.34–1.52); GN-ESRD, OR = 1.91 (95% CI, 1.86–1.96);
after first year: [LN-ESRD, OR = 1.56 (95% CI, 1.45–1.67);
GN-ESRD, OR = 1.39 (95% CI, 1.35–1.44)]. Results in
other sensitivity analyses were also similar (Table 4).
When being transplanted without placement on the wait-
list (which occurred in 1.6%, 1.2%, and 1.0% of patients
with ESRD due to LN, GN, and all other causes, respect-
ively) was combined with placement on the waitlist as anoutcome, associations were only slightly attenuated (data
not shown).
Permanent vascular access
More than one-third of all dialysis patients had a per-
manent vascular access in place at the start of treatment,
but fewer than one-quarter of LN-ESRD patients had a
fistula or graft in place (Table 2). There were no differ-
ences over time in permanent vascular access placement
overall or by cause of ESRD (Table 2). With adjustment,
LN-ESRD patients remained nearly 40% less likely than
other ESRD patients to have a permanent vascular ac-
cess used or in place at first dialysis, whereas GN-ESRD
patients were 10% more likely than other ESRD patients
to have a permanent vascular access (Table 3). Results
were similar in sensitivity analyses (Table 4). Placement
of permanent access was far less common among pa-
tients who recovered function at any point, compared to
those who did not recover function, regardless of attrib-
uted cause (Figure 3). Patients with other causes of
ESRD who had early transplants (within 1 year of ESRD
start) were more likely than similar patients who had
Table 4 Risk ratios for attributed causes of lupus nephritis and other glomerulonephritis vs. other causes of ESRD,
among U.S. ESRD patients initiating treatment 7/05–9/11: sensitivity analyses
Attributed cause
of ESRD
















Pre-ESRD care, yes vs. no (odds ratio)
All other causes 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Lupus nephritis 1.56 (1.46–1.66) 2.02 (1.88–2.17) 1.69 (1.59–1.81) 1.71 (1.61–1.82) 1.55 (1.46–1.65)
Other glomerulonephritis 1.06 (1.04–1.09) 1.20 (1.17–1.23) 1.20 (1.18–1.23) 1.23 (1.20–1.25) 1.22 (1.19–1.24)
Informed of transplant options, yes vs. no (odds ratio)
All other causes 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Lupus nephritis 0.98 (0.91–1.06) 1.16 (1.06–1.26) 1.11 (1.02–1.20) 1.13 (1.04–1.22) 1.09 (1.01–1.18)
Other glomerulonephritis 1.07 (1.03–1.10) 1.19 (1.14–1.23) 1.20 (1.16–1.24) 1.20 (1.16–1.24) 1.19 (1.15–1.23)
Time to placement on the kidney transplant waitlist (hazard ratio)
In 1st year of ESRD
All other causes 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Lupus nephritis 1.53 (1.43–1.63) 1.53 (1.43–1.64) 1.50 (1.41–1.59) 1.44 (1.35–1.53) 1.39 (1.31–1.48)
Other glomerulonephritis 2.01 (1.95–2.06) 1.86 (1.81–1.92) 1.88 (1.83–1.93) 1.93 (1.88–1.98) 1.91 (1.86–1.96)
After 1st year of ESRD
All other causes 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Lupus nephritis 1.56 (1.45–1.67) 1.69 (1.57–1.83) 1.66 (1.54–1.78) 1.57 (1.46–1.69) 1.52 (1.42–1.63)
Other glomerulonephritis 1.36 (1.31–1.41) 1.37 (1.32–1.42) 1.38 (1.33–1.43) 1.41 (1.36–1.46) 1.39 (1.34–1.44)
Permanent vascular access used/in place, yes vs. no (odds ratio)
All other causes 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Lupus nephritis 0.57 (0.53–0.60) 0.63 (0.59–0.67) 0.64 (0.60–0.69) 0.73 (0.68–0.77) 0.61 (0.57–0.65)
Other glomerulonephritis 0.97 (0.95–0.99) 1.10 (1.07–1.12) 1.09 (1.06–1.11) 1.14 (1.12–1.17) 1.10 (1.07–1.12)
*Adjusted for age, race, sex, insurance, body mass index, cardiovascular disease (including pericarditis), and hemoglobin.
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have a permanent vascular access (P < 0.001), but this
was not true among LN-ESRD or GN-ESRD patients
(Figure 3). Among those with early transplants and
with full adjustment, both LN-ESRD (OR = 0.66, 95%
CI, 0.48–0.92) and GN-ESRD (OR = 0.83, 95% CI,
0.74–0.93) patients were less likely than other ESRD
patients to have a permanent vascular access in place
at start of ESRD. For all attributed cause groups, males
were more likely than females to have a permanent vascu-
lar access used or in place at the start of ESRD (P < 0.05
for all causes; Figure 3).
Discussion
Compared to other ESRD patients, LN-ESRD patients
represent a group that may receive greater clinical at-
tention due their underlying SLE and young age. Our
results showed that, indeed, receipt of pre-ESRD neph-
rology care and access to the kidney transplant waitlist
were higher among LN-ESRD vs. other ESRD patients.
After adjustment for differences across the patientpopulations—including age, sex, race, and insurance,
as well as clinical characteristics—LN-ESRD patients
remained more likely than other ESRD patients to have
had pre-ESRD care, to be informed of transplant op-
tions at the start of ESRD, and to be placed on the de-
ceased donor kidney transplant waitlist while on
dialysis. These patterns were similar to those seen in
the comparison of GN-ESRD to other ESRD patients.
However, only about one-quarter of LN-ESRD patients
had a permanent vascular access in place at the start of
dialysis, and LN-ESRD patients remained strikingly less
likely than either GN-ESRD or other ESRD patients to
have a permanent vascular access in place at the start of
dialysis, accounting for patient characteristics.
While LN-ESRD patients were nearly 70% more likely
than other ESRD patients to have pre-ESRD nephrology
care after adjustment for differences in the populations,
nearly one-third of patients with SLE and LN progressed
to ESRD without ever having seen a nephrologist. Fur-
ther, the percentage of patients receiving pre-ESRD care
generally increased slightly over time among most ESRD
Figure 2 Cumulative incidence of placement on the deceased donor kidney transplant waitlist among U.S. ESRD patients initiating
treatment 7/05–9/11, by attributed cause of ESRD. P < 0.001 by log-rank.
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sion of LN is much faster among black patients [33,34],
who are overrepresented in LN and SLE and may also
be less likely to access care early, which may make
nephrology referral prior to development of ESRD
more difficult. It is also possible that progression to
ESRD may be quite rapid among some kidney disease
patients [35]. Particularly among SLE patients, due toFigure 3 Permanent vascular access placement by patient characteris
attributed cause of ESRD. Recovery of renal function is defined as recove
patient returned to dialysis; early transplant is defined as a transplant withinthe relapsing-remitting nature of SLE and LN, poten-
tially involving sudden renal flares [36], it may be diffi-
cult in some cases to refer to nephrology prior to the
urgent need for dialysis. However, it is likely that such
presentations are rare and that, with greater attention
to signs of renal damage and dysfunction (biopsy-proven
GN, hematuria, proteinuria, and reduced glomerular fil-
tration rate) among patients with adequate access to SLEtics, among U.S. ESRD patients initiating treatment 7/05–9/11, by
ry occurring at any time during treatment, regardless of whether
1 year of ESRD start.
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patients could be greatly reduced.
Being informed of transplant options and especially
placement on the kidney transplant waitlist increased
over study follow-up for patients with all attributed
causes of ESRD; these secular trends have been previ-
ously noted in the U.S. LN-ESRD population [27,28].
Changes in criteria for placement on the kidney trans-
plant waitlist that have reduced racial disparities [37,38]
may have resulted in greater access to the waitlist among
the minority LN-ESRD population. Additionally, increas-
ing evidence that transplant outcomes among LN-ESRD
and other ESRD patients appear to be equivalent [39-41]
may have contributed to this increase. While both LN-
ESRD and GN-ESRD patients were more likely to be
placed on the kidney transplant waitlist than patients
with other ESRD, the association was even stronger after
the first year of ESRD among LN-ESRD patients, which
may reflect recommendations to wait to transplant LN-
ESRD patients to allow SLE activity to decrease [42,43].
However, whether such delays are necessary or poten-
tially even detrimental in this population remains in
question [44].
Despite a national quality initiative program initially
implemented in 2003–2004 to increase the use of AVFs
[45], most U.S. ESRD patients started dialysis without a
permanent vascular access in place, and the percentage
with a permanent vascular access at the start of dialysis
did not increase appreciably over study follow-up for
any ESRD group we examined—mirroring recent reports
that show that, while placements of fistulae have in-
creased, the use of temporary catheters has not decreased
substantially [46]. LN-ESRD patients were far less likely
than either GN-ESRD or other ESRD patients to have a
permanent access, a gap that has been noted previously in
pediatric SLE patients [47,48]. While female sex may be
associated with more difficulty placing AVFs [49], greater
likelihood of body image issues associated with permanent
vascular access [50,51], and generally increased complexity
(e.g., contraception and fertility concerns approaching
dialysis), accounting for the female predominance in the
LN-ESRD population did not change the results. Further,
we found that males with LN-ESRD were only slightly
more likely than females with LN-ESRD to have a per-
manent vascular access. The possibility that providers may
skip permanent vascular access among patients who may
receive an early transplant was also not supported by our
findings. Having a permanent vascular access in place at
the start of dialysis was as or more likely among those pa-
tients who received a transplant within a year of ESRD
start than other ESRD patients. Greater anticipated recov-
ery from ESRD among SLE patients could play a role [31],
but we found LN-ESRD patients were less likely than
other patients to have a permanent access in place atdialysis start, regardless of evidence of recovery of renal
function. History of multiple, prolonged intravenous treat-
ments in SLE patients could play a role in decisions not to
refer for vascular access surgery, as could hypercoagulable
states in SLE patients, particularly in the setting of anti-
phospholipid syndrome [43]; however, neither of these
possibilities could be examined with available data. Finally,
many barriers to vascular access that have been noted in
the overall ESRD population, including fear of needles,
issues of coping with thoughts of imminent dialysis, and
the threat of potential physical deformity due to vascular
access [51], may be particularly salient in the younger
LN-ESRD population. Further, follow-up may be less
consistent in this population, preventing providers
from discussing the importance of creating a perman-
ent vascular access.
Similar to the population with ESRD secondary to
sickle cell disease [29], another young, primarily mi-
nority patient population with multiple providers, the
LN-ESRD population showed substantial gaps in place-
ment of permanent vascular access for hemodialysis.
However, unlike the sickle cell population, LN-ESRD
patients were more likely than the general ESRD popu-
lation to receive pre-ESRD care. Such disparate pat-
terns of adequacy of care in LN-ESRD could be the
result of so-called “silos” of care, in which there is lack
of communication and coordination among specialty
providers and a loss of patient-centeredness [52]. Lack
of direct communication between nephrologists and
rheumatologists and the general lack of guidelines in
rheumatology to address preparation for ESRD [30]
may discourage the rheumatologist from actively partici-
pating in certain treatment decisions for their LN-ESRD
patients. While rheumatologists may refer appropriately
to nephrologists, they may leave discussions of specific
preparation for transplantation and dialysis to nephrolo-
gists; in turn, nephrologists may assume that rheumatolo-
gists are coordinating the overall care of the patient
approaching LN-ESRD and spend less time discussing
ESRD preparation with these patients. Such gaps in com-
munication in this critical period could lead to less pre-
paredness for the initiation of ESRD (e.g., placement of
permanent vascular access) but greater access to treat-
ment options (e.g., placement on the kidney transplant
waitlist) after the start of ESRD, when SLE activity may
“burn out” [42].
This study has several limitations. The USRDS does
not capture non-Medicare-eligible individuals who have
untreated ESRD, including some undocumented residents.
Also, attribution of ESRD cause on the CMS-2728 has un-
known validity; only one small validation study has been
published [53], suggesting low sensitivity. There is the po-
tential for selection bias due to missing data (12.0%) in
analyses of pre-ESRD care. Misclassification of quality of
Plantinga et al. BMC Nephrology  (2015) 16:39 Page 10 of 11care measures on the CMS-2728 is also possible, particu-
larly provision of information about kidney transplant
[54], due to variability in provider knowledge about pa-
tients. Many potential confounders, such as hemoglobin
and albumin, may be the result of the adequacy of care,
rather than a factor that leads to adequate care. Such
factors may serve as mediating factors rather than con-
founders, leading to potential overadjustment, although
we found that crude and adjusted results generally did not
differ substantially. As with any observational study,
residual confounding is possible. For example, although
we excluded patients aged ≥ 70 and adjusted for CVD in
the primary analysis, we do not have specific, more granu-
lar data on kidney transplant eligibility, which is likely to
be higher among the LN-ESRD patients and could be a
confounder of the associations with kidney transplant ac-
cess measures. We also could not adjust for acute kidney
injury status leading to ESRD, which might be a marker of
fast progression and provider inability to intervene prior
to start of ESRD, although we were able to examine asso-
ciations among those who never recovered renal function.
This study also has several powerful strengths, including
the capture of all U.S. patients treated for ESRD, limited
loss to follow-up due to universal coverage of ESRD ser-
vices by CMS, and the completion of the CMS-2728 for
all treated patients.
Conclusions
There is room for improvement in all quality-of-care
measures among SLE patients approaching ESRD. While
patients with LN-ESRD are more likely to receive pre-
ESRD care and have better access to transplant than
patients with ESRD due to other causes, they are far less
likely than their counterparts to have a permanent
vascular access in place for dialysis. Further studies are
warranted to specifically examine patient-, provider-,
and system-level barriers to permanent vascular access
placement and to estimate the morbidity and mortality
associated with temporary access in the LN-ESRD popula-
tion, as well as to examine potential barriers to adequate
ESRD care in patients with SLE.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LCP, CD, WM, and SSL contributed to the conception and design of the
study. REP acquired the data. LCP performed the analysis and LCP, REP, and
CD interpreted the data. LCP drafted the manuscript and REP, CD, SOP, WM,
JC, and SSL revised the manuscript critically for important intellectual
content. All authors read and approved the final manuscript. LCP takes full
responsibility for the accuracy and integrity of this work.
Acknowledgements
The data reported here have been supplied by the United States Renal Data
System (USRDS). The interpretation and reporting of these data are the
responsibility of the authors and in no way should be seen as an official
policy or interpretation of the U.S. government. L.C.P. was supported byLaney Graduate School, Emory University. R.E.P. was supported in part by
grants from the National Center for Advancing Translational Sciences of the
National Institutes of Health (NIH; ULl TR000454 and KL2TR000455). R.E.P. and
S.O.P are both supported in part by R24MD008077-01 through the National
Institute on Minority Health and Health Disparities. C.D. and S.S.L. are supported
in part by NIH R01AR065493 and CDC U01DP005119. The content is solely the
responsibility of the authors and does not necessarily represent the official
views of the NIH.
Author details
1Department of Medicine, Emory University, Atlanta, Georgia, USA.
2Department of Surgery, Emory University, Atlanta, Georgia, USA. 3Emory
Transplant Center, Emory Healthcare, Atlanta, Georgia, USA. 4Department of
Epidemiology, Emory University, Atlanta, Georgia, USA.
Received: 8 December 2014 Accepted: 18 March 2015References
1. Astor BC, Eustace JA, Powe NR, Klag MJ, Sadler JH, Fink NE, et al. Timing of
nephrologist referral and arteriovenous access use: the CHOICE Study. Am J
Kidney Dis. 2001;38:494–501.
2. Avorn J, Winkelmayer WC, Bohn RL, Levin R, Glynn RJ, Levy E, et al. Delayed
nephrologist referral and inadequate vascular access in patients with
advanced chronic kidney failure. J Clin Epidemiol. 2002;55:711–6.
3. Winkelmayer WC, Glynn RJ, Levin R, Owen Jr W, Avorn J. Late referral and
modality choice in end-stage renal disease. Kidney Int. 2001;60:1547–54.
4. Winkelmayer WC, Glynn RJ, Levin R, Mittleman MA, Pliskin JS, Avorn J. Late
nephrologist referral and access to renal transplantation. Transplantation.
2002;73:1918–23.
5. Winkelmayer WC, Owen Jr WF, Levin R, Avorn J. A propensity analysis of
late versus early nephrologist referral and mortality on dialysis. J Am Soc
Nephrol. 2003;14:486–92.
6. Kinchen KS, Sadler J, Fink N, Brookmeyer R, Klag MJ, Levey AS, et al. The
timing of specialist evaluation in chronic kidney disease and mortality. Ann
Intern Med. 2002;137:479–86.
7. Stack AG. Impact of timing of nephrology referral and pre-ESRD care on
mortality risk among new ESRD patients in the United States. Am J Kidney
Dis. 2003;41:310–8.
8. Kazmi WH, Obrador GT, Khan SS, Pereira BJ, Kausz AT. Late nephrology
referral and mortality among patients with end-stage renal disease: a
propensity score analysis. Nephrol Dial Transplant. 2004;19:1808–14.
9. Hasegawa T, Bragg-Gresham JL, Yamazaki S, Fukuhara S, Akizawa T, Kleophas
W, et al. Greater first-year survival on hemodialysis in facilities in which
patients are provided earlier and more frequent pre-nephrology visits. Clin J
Am Soc Nephrol. 2009;4:595–602.
10. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K. Comparison of survival
probabilities for dialysis patients vs cadaveric renal transplant recipients.
J Am Med Assoc. 1993;270:1339–43.
11. Ojo AO, Port FK, Wolfe RA, Mauger EA, Williams L, Berling DP. Comparative
mortality risks of chronic dialysis and cadaveric transplantation in black
end-stage renal disease patients. Am J Kidney Dis. 1994;24:59–64.
12. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al.
Comparison of mortality in all patients on dialysis, patients on dialysis
awaiting transplantation, and recipients of a first cadaveric transplant.
N Engl J Med. 1999;341:1725–30.
13. Kutner NG. Improving compliance in dialysis patients: does anything work?
Semin Dial. 2001;14:324–7.
14. Evans RW, Manninen DL, Garrison Jr LP, Hart LG, Blagg CR, Gutman RA, et al.
The quality of life of patients with end-stage renal disease. N Engl J Med.
1985;312:553–9.
15. United States Renal Data System. USRDS 2013 annual data report: atlas of
chronic kidney disease and end-stage renal disease in the United States.
Bethesda, MD, National Institutes of Health, National Institute of Diabetes
and Digestive and Kidney Diseases. 2013. Available at: www.usrds.org.
16. Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B,
et al. Vascular access use in Europe and the United States: results from the
DOPPS. Kidney Int. 2002;61:305–16.
17. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access
morbidity. J Am Soc Nephrol. 1996;7:523–35.
Plantinga et al. BMC Nephrology  (2015) 16:39 Page 11 of 1118. Lee H, Manns B, Taub K, Ghali WA, Dean S, Johnson D, et al. Cost analysis of
ongoing care of patients with end-stage renal disease: the impact of dialysis
modality and dialysis access. Am J Kidney Dis. 2002;40:611–22.
19. Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of
vascular access and mortality in U.S. hemodialysis patients. Kidney Int.
2001;60:1443–51.
20. Woods JD, Port FK. The impact of vascular access for haemodialysis on
patient morbidity and mortality. Nephrol Dial Transplant. 1997;12:657–9.
21. Xue JL, Dahl D, Ebben JP, Collins AJ. The association of initial hemodialysis
access type with mortality outcomes in elderly Medicare ESRD patients. Am
J Kidney Dis. 2003;42:1013–9.
22. Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG. Vascular access and
all-cause mortality: a propensity score analysis. J Am Soc Nephrol.
2004;15:477–86.
23. Pastan S, Soucie JM, McClellan WM. Vascular access and increased risk of
death among hemodialysis patients. Kidney Int. 2002;62:620–6.
24. Office of Disease Prevention and Health Promotion. Healthy people 2020.
Washington, DC: U.S. Department of Health and Human Services; 2015.
Available at: www.healthypeople.gov.
25. Centers for Medicare & Medicaid Services. Final CY 2014 end-stage renal
disease prospective payment system. Department of Health and Human
Services; Reg. No. CMS-1526-F, 12/2/2013. Available at: http://www.gpo.gov/
fdsys/pkg/FR-2013-1202/pdf/2013-28451.pdf.
26. Plantinga L, Drenkard C, Patzer R, Klein M, Kramer M, Pastan S, et al.
Sociodemographic and geographic predictors of quality of care in U.S.
patients with end-stage renal disease due to lupus nephritis. Arthritis
Rheumatol. 2015;67:761–72.
27. Costenbader KH, Desai A, Alarcon GS, Hiraki LT, Shaykevich T, Brookhart MA,
et al. Trends in the incidence, demographics, and outcomes of end-stage
renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis
Rheum. 2011;63:1681–8.
28. Hiraki LT, Lu B, Alexander SR, Shaykevich T, Alarcon GS, Solomon DH, et al.
End-stage renal disease due to lupus nephritis among children in the US,
1995–2006. Arthritis Rheum. 2011;63:1988–97.
29. McClellan AC, Luthi JC, Lynch JR, Soucie JM, Kulkarni R, Guasch A, et al. High
one year mortality in adults with sickle cell disease and end-stage renal
disease. Br J Haematol. 2012;159:360–7.
30. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD,
et al. American College of rheumatology guidelines for screening,
treatment, and management of lupus nephritis. Arthritis Care Res.
2012;64:797–808.
31. Mohan S, Huff E, Wish J, Lilly M, Chen SC, McClellan WM. Recovery of renal
function among ESRD patients in the US medicare program. PLoS One.
2013;8:e83447.
32. Korbet SM, Schwartz MM, Evans J, Lewis EJ. Severe lupus nephritis: racial
differences in presentation and outcome. J Am Soc Nephrol.
2007;18:244–54.
33. McAdams-DeMarco MA, James N, Salter ML, Walston J, Segev DL. Trends in
kidney transplant outcomes in older adults. J Am Geriatr Soc.
2014;62:2235–42.
34. Freedman BI, Langefeld CD, Andringa KK, Croker JA, Williams AH, Garner NE,
et al. End-stage renal disease in African Americans with lupus nephritis is
associated with APOL1. Arthritis Rheumatol. 2014;66:390–6.
35. O’Hare AM, Batten A, Burrows NR, Pavkov ME, Taylor L, Gupta I, et al.
Trajectories of kidney function decline in the 2 years before initiation of
long-term dialysis. Am J Kidney Dis. 2012;59:513–22.
36. Mosca M, Bencivelli W, Neri R, Pasquariello A, Batini V, Puccini R, et al. Renal
flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney
Int. 2002;61:1502–9.
37. Ashby VB, Port FK, Wolfe RA, Wynn JJ, Williams WW, Roberts JP, et al.
Transplanting kidneys without points for HLA-B matching: consequences of
the policy change. Am J Transplant. 2011;11:1712–8.
38. Hall EC, Massie AB, James NT, Garonzik Wang JM, Montgomery RA, Berger
JC, et al. Effect of eliminating priority points for HLA-B matching on racial
disparities in kidney transplant rates. Am J Kidney Dis. 2011;58:813–6.
39. Contreras G, Mattiazzi A, Guerra G, Ortega LM, Tozman EC, Li H, et al.
Recurrence of lupus nephritis after kidney transplantation. J Am Soc
Nephrol. 2010;21:1200–7.
40. Ward MM. Outcomes of renal transplantation among patients with end-stage
renal disease caused by lupus nephritis. Kidney Int. 2000;57:2136–43.41. Bunnapradist S, Chung P, Peng A, Hong A, Chung P, Lee B, et al. Outcomes
of renal transplantation for recipients with lupus nephritis: analysis of the
organ procurement and transplantation network database. Transplantation.
2006;82:612–8.
42. Mojcik CF, Klippel JH. End-stage renal disease and systemic lupus erythematosus.
Am J Med. 1996;101:100–7.
43. Moroni G, Tantardini F, Ponticelli C. Renal replacement therapy in lupus
nephritis. J Nephrol. 2003;16:787–91.
44. Plantinga LC, Patzer RE, Drenkard C, Kramer MR, Klein M, Lim SS, et al.
Association of time to kidney transplantation with graft failure among U.S.
patients with end-stage renal disease due to lupus nephritis. Arthritis Care
Res. 2015;67:571–81.
45. Lynch JR, Mohan S, McClellan WM. Achieving the goal: results from the
fistula first breakthrough initiative. Curr Opin Nephrol Hypertens.
2011;20:583–92.
46. Vassalotti JA, Jennings WC, Beathard GA, Neumann M, Caponi S, Fox CH,
et al. Fistula first breakthrough initiative: targeting catheter last in fistula first.
Semin Dial. 2012;25:303–10.
47. Sule SD, Fadrowski JJ, Fivush BA, Gorman G, Furth SL. Reduced albumin
levels and utilization of arteriovenous access in pediatric patients with
systemic lupus erythematosus (SLE). Pediatr Nephrol. 2007;22:2041–6.
48. Sule SD, Fadrowski JJ, Fivush BA, Neu AM, Furth SL. Persistent low albumin
and temporary vascular access in pediatric patients with SLE on
hemodialysis. Pediatr Nephrol. 2009;24:1981–7.
49. Sato Y, Miyamoto M, Sueki S, Sakurada T, Kimura K, Nakazawa R, et al. Risk
factors associated with inadequate veins for placement of arteriovenous
fistulas for hemodialysis. J Artif Organs. 2013;16:469–74.
50. Muringai T, Noble H, McGowan A, Channey M. Dialysis access and the
impact on body image: role of the nephrology nurse. Br J Nurs.
2008;17:362–6.
51. Casey JR, Hanson CS, Winkelmayer WC, Craig JC, Palmer S, Strippoli GF, et al.
Patients’ perspectives on hemodialysis vascular access: a systematic review
of qualitative studies. Am J Kidney Dis. 2014;64(6):937–53.
52. Institute of Medicine. Crossing the quality chasm: a new health system for
the 21st century. Washington, DC: National Academy Press; 2001.
53. Layton JB, Hogan SL, Jennette CE, Kenderes B, Krisher J, Jennette JC, et al.
Discrepancy between medical evidence form 2728 and renal biopsy for
glomerular diseases. Clin J Am Soc Nephrol. 2010;5:2046–52.
54. Salter ML, Orandi B, McAdams-DeMarco MA, Law A, Meoni LA, Jaar BG, et al.
Patient- and provider-reported information about transplantation and
subsequent waitlisting. J Am Soc Nephrol. 2014;25:2871–7.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
